{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-26-000009","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2026-05-12T20:07:20+00:00","discovered_at":"2026-05-12T20:09:01.315855+00:00","generated_at":"2026-05-12T21:25:38.727432+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SELLAS reports 78 events in REGAL AML trial; Q1 net loss $8.4M, cash $107.1M","bullets":["78 events (deaths) occurred in pivotal Phase 3 REGAL trial of GPS in AML as of May 11; final analysis triggered at 80th event.","Cash and cash equivalents $107.1M at March 31, 2026; additional $7.5M from warrant exercises received in Q2 2026.","Net loss $8.4M for Q1 2026 ($0.05 per share) vs $5.8M loss ($0.07 per share) in Q1 2025.","Phase 2 trial of SLS009 in first-line AML dosing patients; topline data expected in Q4 2026.","R&D expenses $5.1M (up from $3.2M); G&A $4.1M (up from $2.9M) driven by BLA preparation and professional fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-26-000009","json":"https://secwatch.observer/filing/0001390478-26-000009.json","markdown":"https://secwatch.observer/filing/0001390478-26-000009.md","text":"https://secwatch.observer/filing/0001390478-26-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047826000009/0001390478-26-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047826000009/sls-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:25:38.727432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}